Glycobond is a company with origins in the medical faculty and the department of BKV at Linköping University. The company was founded in 2011 and its focus is on liver disease and cancer and is a spin-off of research carried out at Linköping University. Its first product is an HCC (Hepatocellular Carcinoma) diagnosis assay, HepaCheC®. Early diagnosis of HCC is essential for successful treatment. Today, only 10% of HCC patients are diagnosed at an early stage. Therefore, there is an unmet need for diagnostic markers that enable early detection. The company’s first product is an assay to aid in the diagnosis of primary liver cancer. Additionally, Glycobond’s first developed recombinant peptide, Mono-F, has demonstrated unique and innovative properties and has received patent protection in several countries.